Biofrontera Inc. (BFRI)
1.13
-0.02 (-1.74%)
At close: Feb 20, 2025, 3:59 PM
1.15
2.22%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.11 |
| Market Cap | 9.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.16 |
| PE Ratio (ttm) | 0.97 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 40,199 |
| Avg. Volume (20D) | 867,201 |
| Open | 1.15 |
| Previous Close | 1.15 |
| Day's Range | 1.10 - 1.15 |
| 52-Week Range | 0.65 - 2.43 |
| Beta | undefined |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-m...
Sector Healthcare
IPO Date Oct 29, 2021
Employees 83
Stock Exchange NASDAQ
Ticker Symbol BFRI
Website https://www.biofrontera.us.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BFRI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 522.22% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Biofrontera Inc. is scheduled to release its earnings on Mar 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.31%
Biofrontera shares are trading higher after the co...
Unlock content with
Pro Subscription
3 months ago
-15.38%
Biofrontera shares are trading lower after the company reported worse-than-expected Q3 financial results.
